Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium

Jianmin Zhang, Song Yao, Qiang Hu, Qianqian Zhu, Song Liu, Kathryn L. Lunetta, Stephen A. Haddad, Nuo Yang, He Shen, Chi Chen Hong, Lara Sucheston-Campbell, Edward A. Ruiz-Narvaez, Jeannette T. Bensen, Melissa A. Troester, Elisa V. Bandera, Lynn Rosenberg, Christopher A. Haiman, Andrew F. Olshan, Julie R. Palmer, Christine B. Ambrosone

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


The Hippo signaling pathway regulates cellular proliferation and survival, thus exerting profound effects on normal cell fate and tumorigenesis. Dysfunction of the Hippo pathway components has been linked with breast cancer stem cell regulation, as well as breast tumor progression and metastasis. TAZ, a key component of the Hippo pathway, is highly expressed in triple negative breast cancer; however, the associations of genetic variations in this important pathway with breast cancer risk remain largely unexplored. Here, we analyzed 8309 germline variants in 15 genes from the Hippo pathway with a total of 3663 cases and 4687 controls from the African American Breast Cancer Epidemiology and Risk Consortium. Odds ratios (ORs) were estimated using logistic regression for overall breast cancer, by estrogen receptor (ER) status (1983 ER positive and 1098 ER negative), and for case-only analyses by ER status. The Hippo signaling pathway was significantly associated with ER-negative breast cancer (pathway level P = 0.02). Gene-based analyses revealed that CDH1 was responsible for the pathway association (P < 0.01), with rs4783673 in CDH1 statistically significant after gene-level adjustment for multiple comparisons (P = 9.2×10-5, corrected P = 0.02). rs142697907 in PTPN14 was associated with ER-positive breast cancer and rs2456773 in CDK1 with ER-negativity in case-only analysis after gene-level correction for multiple comparisons (corrected P < 0.05). In conclusion, common genetic variations in the Hippo signaling pathway may contribute to both ER-negative and ER+ breast cancer risk in AA women.

Original languageEnglish (US)
Article numberbgw077
Pages (from-to)951-956
Number of pages6
Issue number10
StatePublished - Oct 1 2016

All Science Journal Classification (ASJC) codes

  • Cancer Research


Dive into the research topics of 'Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium'. Together they form a unique fingerprint.

Cite this